A major change in federal cannabis policy could reshape conversations across healthcare, pharmacy, addiction medicine, and public policy. The U.S. Department of Justice has moved state-licensed medical marijuana from Schedule I to Schedule III, signaling a historic shift in how medical cannabis is regulated at the federal level.

A major change in federal cannabis policy could reshape conversations across healthcare, pharmacy, addiction medicine, and public policy. The U.S. Department of Justice has moved state-licensed medical marijuana from Schedule I to Schedule III, signaling a historic shift in how medical cannabis is regulated at the federal level.

A major change in federal cannabis policy could reshape conversations across healthcare, pharmacy, addiction medicine, and public policy. The U.S. Department of Justice has moved state-licensed medical marijuana from Schedule I to Schedule III, signaling a historic shift in how medical cannabis is regulated at the federal level. While the order does not legalize marijuana under federal law, it does reduce regulatory barriers, expand opportunities for cannabis research, and allow licensed medical marijuana businesses to deduct standard business expenses on federal taxes.

A new commentary in the Journal of Ageing and Longevity argues that the senior living industry is overdue for a fundamental redesign, one that shifts away from hospitality-driven models toward integrated, person-centered healthcare ecosystems.

With the U.S. population aged 65+ projected to exceed 80 million by 2040, current senior living models, largely built for healthier, more independent residents decades ago, are increasingly misaligned with today’s complex care needs.

On April 18th, 2026, President Trump signed an executive order easing federal restrictions on psychedelic substances with aims to accelerate research into psychedelic treatments for mental health. The executive order represents a softening of federal policy towards psychedelics and is being framed as a potential tool to address unmet mental health needs, particularly among veterans.

AI-powered mental health chatbots are rapidly expanding as “therapy in your pocket,” but a recent Washington Post report warns that the boom is outpacing safeguards. The article describes a crowded market of behavioral health AI tools that promise affordable, always-available support, even though many have limited clinical validation and inconsistent oversight.

In a recent LinkedIn update, The Braff Group described the current M&A climate as a “battle between macroeconomic headwinds and acquisition demand,” with buyer demand still winning—particularly in behavioral health, where several segments have outperformed other healthcare services. Drawing from its 2025 Behavioral Health Year-End M&A Update, Braff notes that uncertainty around inflation, interest rates, tariffs, and changing coverage dynamics has not stopped buyers from pursuing high-quality behavioral health assets.

A rapidly aging U.S. population is transforming senior mental health from a historically overlooked niche into a central healthcare priority and a major investment opportunity. According to TripleTree, this shift is being driven by both demographic expansion and increasing clinical complexity among older adults.

A recent study in the Journal of Addiction Medicine examines how individuals who use drugs—particularly nonprescribed stimulants—perceive opioid overdose risk and the barriers and facilitators to prevention strategies such as naloxone distribution. The findings highlight a critical disconnect between actual overdose risk and personal risk perception, a factor that continues to drive preventable deaths in the U.S. opioid crisis.